COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,833 Articles (22,553 medRxiv, 8,280 bioRxiv)

Most recent first Previous |  Page 973: Articles 9721-9730  | Next

Fully Vaccinated and Boosted Patients Requiring Hospitalization for COVID-19: an Observational Cohort Analysis
Mielke, N., Johnson, S., Bahl, A.
10.1101/2022.01.05.22268626 — Posted: 2022-01-05 Discussion: Onsite
SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein
Walter, M., Chen, I. P., Vallejo-Gracia, A., Kim, I.-J., Bielska, O., Lam, V. L., Hayashi, J. M., Cruz, A., Shah, S., Gross, J. D., Krogan, N. J., Schilling, B., Ott, M., Verdin, E.
10.1101/2022.01.04.474979 — Posted: 2022-01-05
SARS-CoV-2 Infection of Microglia Elicits Pro-inflammatory Activation and Apoptotic Cell Death
Jeong, G. U., Lyu, J., Kim, K.-D., Chung, Y. C., Yoon, G. Y., Lee, S., Hwang, I., Shin, W.-H., Ko, J., Lee, J.-Y., Kwon, Y.-C.
10.1101/2022.01.04.475015 — Posted: 2022-01-05
Towards an optimal monoclonal antibody with higher binding affinity to the receptor-binding domain of SARS-CoV-2 spike proteins from different variants
Neamtu, A., Mocci, F., Laaksonen, A., Barroso da Silva, F. L.
10.1101/2022.01.04.474958 — Posted: 2022-01-05
Computational study of the furin cleavage domain of SARS-CoV-2: delta binds strongest of extant variants
Jawaid, M. Z., Baidya, A., Jakovcevic, S., Lusk, J., Mahboubi-Ardakani, R., Solomon, N., Gonzalez, G., Arsuaga, J., Vazquez, M., Davis, R. L., Cox, D. L.
10.1101/2022.01.04.475011 — Posted: 2022-01-05
Genomic perspectives on the emerging SARS-CoV-2 Omicron variant
Ma, W., Yang, J., Fu, H., Su, C., Yu, C., Wang, Q., de Vasconcelos, A. T. R., Bazykin, G., Bao, Y., Li, M.
10.1101/2022.01.05.474231 — Posted: 2022-01-05
Sequence assignment validation in cryo-EM models with checkMySequence
Chojnowski, G.
10.1101/2022.01.04.474974 — Posted: 2022-01-05
An elite broadly neutralizing antibody protects SARS-CoV-2 Omicron variant challenge
Zhou, B., Zhou, R., Chan, J. F.-W., Luo, M., Peng, Q., Yuan, S., Mok, B. W.-Y., Chen, B., Wang, P., Poon, V. K.-M., Chu, H., Chan, C. C.-S., Tsang, J. O.-L., Chan, C. C.-Y., Au, K.-K., Man, H.-O., Lu, L., To, K. K.-W., Chen, H., Yuen, K.-Y., Chen, Z.
10.1101/2022.01.05.475037 — Posted: 2022-01-05
Performance evaluation of novel fluorescent-based lateral immune flow assay (LIFA) for rapid detection and quantitation of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals
Shurrab, F. M., Younes, N., Al-Sadeq, D. W., Qotba, H., Abu-Raddad, L. J., Nasrallah, G.
10.1101/2022.01.04.22268717 — Posted: 2022-01-05
COVID-19 vaccination status is associated with physical activity in German-speaking countries: the COR-PHYS-Q cohort study
Schwendinger, F., Boeck, H. T., Infanger, D., Faulhaber, M., Tegtbur, U., Schmidt-Trucksäss, A.
10.1101/2022.01.01.21268576 — Posted: 2022-01-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).